 Axovant Gene Therapies Ltd. AXGT, a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it has completed enrollment in the low-dose cohort of the Phase 12 Stage 1 study for Type II late infantile and juvenile onset GM1 patients evaluating safety, tolerability, and exploratory measures of efficacy at a dose of 1.5x1013 vgkg delivered intravenously. There are currently no approved treatments for GM1 gangliosidosis. 